AJMC Staff

An update on the latest developments in the world of oncology care: product approvals, clinical developments, health policy changes, and more.

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press

Intuniv, a once-daily non-stimulant from Shire and Shionogi for adults with attention-deficit/hyperactivity disorder, met its primary endpoint and showed a superior change from baseline compared with placebo in a phase 3 study.

Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular disease, making it important to assess the risk factors that influence RA so physicians can better treat high-risk patients.

Coverage of our peer-reviewed research in the healthcare and mainstream press.

Coverage of our peer-reviewed research in the healthcare and mainstream press.